+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

From
Liver Cirrhosis - Pipeline Insight, 2024 - Product Thumbnail Image

Liver Cirrhosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 180 Pages
  • Global
From
Renal Anemia - Pipeline Insight, 2024 - Product Thumbnail Image

Renal Anemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Lupus Nephritis - Pipeline Insight, 2024 - Product Thumbnail Image

Lupus Nephritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Hepatitis D - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatitis D - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Hepatitis A - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatitis A - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Glomerulonephritis - Pipeline Insight, 2024 - Product Thumbnail Image

Glomerulonephritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Polycystic Kidney Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Polycystic Kidney Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Primary biliary cirrhosis - Pipeline Insight, 2024 - Product Thumbnail Image

Primary biliary cirrhosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 120 Pages
  • Global
From
Pyelonephritis - Pipeline Insight, 2024 - Product Thumbnail Image

Pyelonephritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Hyperoxaluria - Pipeline Insight, 2024 - Product Thumbnail Image

Hyperoxaluria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Hyperkalemia - Pipeline Insight, 2024 - Product Thumbnail Image

Hyperkalemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Urea Cycle Disorders - Pipeline Insight, 2024 - Product Thumbnail Image

Urea Cycle Disorders - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Liver Failure - Pipeline Insight, 2024 - Product Thumbnail Image

Liver Failure - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 70 Pages
  • Global
From
Cirrhosis - Pipeline Insight, 2024 - Product Thumbnail Image

Cirrhosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 200 Pages
  • Global
From
Hepatitis C Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatitis C Virus Infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Complement 3 Glomerulopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Complement 3 Glomerulopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Autoimmune Hepatitis - Pipeline Insight, 2024 - Product Thumbnail Image

Autoimmune Hepatitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Autosomal dominant polycystic kidney disease - Pipeline Insight, 2024 - Product Thumbnail Image

Autosomal dominant polycystic kidney disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 75 Pages
  • Global
From
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more